<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01504672</url>
  </required_header>
  <id_info>
    <org_study_id>UmU-2011-148-31M</org_study_id>
    <nct_id>NCT01504672</nct_id>
  </id_info>
  <brief_title>An Intervention Study to Reduce Drug-related Problems and Readmissions Among Old People With Dementia</brief_title>
  <official_title>A Randomized Controlled Pharmacist Intervention Study to Reduce Drug-related Problems and Readmissions Among Old People With Dementia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Umeå University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Umeå University</source>
  <brief_summary>
    <textblock>
      The aim of this randomized controlled study is to investigate if medication reviews performed&#xD;
      by a clinical pharmacist as part of a ward team can reduce drug related problems and reduce&#xD;
      readmissions to hospital among elderly patients (≥65 years) with dementia and cognitive&#xD;
      failure.&#xD;
&#xD;
      Four hundred and sixty patients will be recruited and randomized to control (usual care) and&#xD;
      intervention group (enhanced service in which a pharmacist is part of the health care team).&#xD;
&#xD;
      Six months after the last patient of the 460 has been discharged the study will be closed.&#xD;
      Data about the number of readmissions and visits to the emergency room will be collected&#xD;
      during the six-month follow-up and also, the costs associated with each visit or admission.&#xD;
      Time until institutionalization will be compared between intervention group and control&#xD;
      group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Readmitted Because of Drug Related Reasons</measure>
    <time_frame>Six months follow-up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cost for Visits for Readmissions and to the Emergency Department Compared Between Patients in the Control Group and Intervention Group.</measure>
    <time_frame>Six months follow-up</time_frame>
    <description>To evaluate the economic impact of clinical pharmacist engagement in hospital ward teams for medication therapy management in older patients with dementia or cognitive impairments.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Institutionalized After Discharge, in Control Group and Intervention Group.</measure>
    <time_frame>Six months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Emergency Department Visits During the 6-month Follow-up.</measure>
    <time_frame>Six months follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Number of Participants With Potentially Inappropriate Medications, According to the Swedish National Board of Health and Welfare, at Admission and Discharge Between Intervention and Control Group</measure>
    <time_frame>Index admission (at randomization) and index discharge (duration of index admission, mean days 8.7)</time_frame>
    <description>Six drug-specific quality indicators as defined by the Swedish National Board of Health and Welfare were used to define use of Potentially inappropriate medications (PIMs) in this study. Four out of the six selected indicators belong to a group where drug-use should be as low as possible regardless of indication: anticholinergic drugs (as defined by the Swedish National Board of Health and Welfare, propiomazine, tramadol, and long-acting benzodiazepines. The two remaining indicators are classified as preparations for which correct and current indication is of particular importance: antipsychotic drugs (N05A except lithium) and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). In the present study, a PIM was defined as exposure to at least one of the drugs mentioned among the six quality indicators.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">460</enrollment>
  <condition>Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Medication review</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medication review</intervention_name>
    <description>In the intervention, the pharmacist will evaluate:&#xD;
Is there an indication for the drug?&#xD;
Has the drug desired effect?&#xD;
Is the dose correct and dosing scheme correct?&#xD;
Side effects, contraindications, inappropriate drugs&#xD;
Interactions&#xD;
Treatment time&#xD;
Cost effectiveness&#xD;
Adherence to recommendation list&#xD;
Problems with handling the drugs (for example crushing of the tablets)&#xD;
Untreated indication&#xD;
Double medications&#xD;
Administration of drugs</description>
    <arm_group_label>Medication review</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with dementia or cognitive impairment&#xD;
&#xD;
          -  Patients ≥ 65 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients previously admitted to the study wards during the study period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugo Lövheim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Umeå University, Umeå, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>County hospital of Skellefteå</name>
      <address>
        <city>Skellefteå</city>
        <zip>931 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umeå University Hospital</name>
      <address>
        <city>Umeå</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 3, 2012</study_first_submitted>
  <study_first_submitted_qc>January 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2012</study_first_posted>
  <results_first_submitted>October 27, 2017</results_first_submitted>
  <results_first_submitted_qc>October 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 9, 2021</results_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Umeå University</investigator_affiliation>
    <investigator_full_name>Hugo Lovheim</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Drug related problems</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intervention Group</title>
          <description>Medication review: In the intervention, the pharmacist will evaluate:&#xD;
Is there an indication for the drug?&#xD;
Has the drug desired effect?&#xD;
Is the dose correct and dosing scheme correct?&#xD;
Side effects, contraindications, inappropriate drugs&#xD;
Interactions&#xD;
Treatment time&#xD;
Cost effectiveness&#xD;
Adherence to recommendation list&#xD;
Problems with handling the drugs (for example crushing of the tablets)&#xD;
Untreated indication&#xD;
Double medications&#xD;
Administration of drugs</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Usual Care where no medication review is performed by clinical pharmacists</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="230"/>
                <participants group_id="P2" count="230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="212"/>
                <participants group_id="P2" count="217"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intervention Group</title>
          <description>An intervention as described is performed for the people in the intervention group.</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>No intervention is performed.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="212"/>
            <count group_id="B2" value="217"/>
            <count group_id="B3" value="429"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="217"/>
                    <measurement group_id="B3" value="429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.1" spread="6.6"/>
                    <measurement group_id="B2" value="83.1" spread="6.6"/>
                    <measurement group_id="B3" value="83.1" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="138"/>
                    <measurement group_id="B3" value="271"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="217"/>
                    <measurement group_id="B3" value="429"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medical history</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Heart failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac arrhythmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes Mellitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COPD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant disease, past or present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke, past</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Readmitted Because of Drug Related Reasons</title>
        <time_frame>Six months follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Medication review: In the intervention, the pharmacist will evaluate:&#xD;
Is there an indication for the drug?&#xD;
Has the drug desired effect?&#xD;
Is the dose correct and dosing scheme correct?&#xD;
Side effects, contraindications, inappropriate drugs&#xD;
Interactions&#xD;
Treatment time&#xD;
Cost effectiveness&#xD;
Adherence to recommendation list&#xD;
Problems with handling the drugs (for example crushing of the tablets)&#xD;
Untreated indication&#xD;
Double medications&#xD;
Administration of drugs</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual Care where no medication review is performed by clinical pharmacists</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Readmitted Because of Drug Related Reasons</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cost for Visits for Readmissions and to the Emergency Department Compared Between Patients in the Control Group and Intervention Group.</title>
        <description>To evaluate the economic impact of clinical pharmacist engagement in hospital ward teams for medication therapy management in older patients with dementia or cognitive impairments.</description>
        <time_frame>Six months follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Medication Review</title>
            <description>Medication review: In the intervention, the pharmacist will evaluate:&#xD;
Is there an indication for the drug?&#xD;
Has the drug desired effect?&#xD;
Is the dose correct and dosing scheme correct?&#xD;
Side effects, contraindications, inappropriate drugs&#xD;
Interactions&#xD;
Treatment time&#xD;
Cost effectiveness&#xD;
Adherence to recommendation list&#xD;
Problems with handling the drugs (for example crushing of the tablets)&#xD;
Untreated indication&#xD;
Double medications&#xD;
Administration of drugs</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
          </group>
        </group_list>
        <measure>
          <title>Cost for Visits for Readmissions and to the Emergency Department Compared Between Patients in the Control Group and Intervention Group.</title>
          <description>To evaluate the economic impact of clinical pharmacist engagement in hospital ward teams for medication therapy management in older patients with dementia or cognitive impairments.</description>
          <units>Euro</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2340" spread="0"/>
                    <measurement group_id="O2" value="2630" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Institutionalized After Discharge, in Control Group and Intervention Group.</title>
        <time_frame>Six months follow-up</time_frame>
        <population>Of the 460 people included in this study, 31 deceased before discharge. Of the remaining 429 persons, 146+158=304 persons lived at home, and these were included in the analysis. The remaining 125 were already living in nursing homes and were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Medication review: In the intervention, the pharmacist will evaluate:&#xD;
Is there an indication for the drug?&#xD;
Has the drug desired effect?&#xD;
Is the dose correct and dosing scheme correct?&#xD;
Side effects, contraindications, inappropriate drugs&#xD;
Interactions&#xD;
Treatment time&#xD;
Cost effectiveness&#xD;
Adherence to recommendation list&#xD;
Problems with handling the drugs (for example crushing of the tablets)&#xD;
Untreated indication&#xD;
Double medications&#xD;
Administration of drugs</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual Care where no medication review is performed by clinical pharmacists</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Institutionalized After Discharge, in Control Group and Intervention Group.</title>
          <population>Of the 460 people included in this study, 31 deceased before discharge. Of the remaining 429 persons, 146+158=304 persons lived at home, and these were included in the analysis. The remaining 125 were already living in nursing homes and were not included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Emergency Department Visits During the 6-month Follow-up.</title>
        <time_frame>Six months follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Medication review: In the intervention, the pharmacist will evaluate:&#xD;
Is there an indication for the drug?&#xD;
Has the drug desired effect?&#xD;
Is the dose correct and dosing scheme correct?&#xD;
Side effects, contraindications, inappropriate drugs&#xD;
Interactions&#xD;
Treatment time&#xD;
Cost effectiveness&#xD;
Adherence to recommendation list&#xD;
Problems with handling the drugs (for example crushing of the tablets)&#xD;
Untreated indication&#xD;
Double medications&#xD;
Administration of drugs</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual Care where no medication review is performed by clinical pharmacists</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Emergency Department Visits During the 6-month Follow-up.</title>
          <units>All-cause emergency department visits</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190"/>
                    <measurement group_id="O2" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Number of Participants With Potentially Inappropriate Medications, According to the Swedish National Board of Health and Welfare, at Admission and Discharge Between Intervention and Control Group</title>
        <description>Six drug-specific quality indicators as defined by the Swedish National Board of Health and Welfare were used to define use of Potentially inappropriate medications (PIMs) in this study. Four out of the six selected indicators belong to a group where drug-use should be as low as possible regardless of indication: anticholinergic drugs (as defined by the Swedish National Board of Health and Welfare, propiomazine, tramadol, and long-acting benzodiazepines. The two remaining indicators are classified as preparations for which correct and current indication is of particular importance: antipsychotic drugs (N05A except lithium) and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). In the present study, a PIM was defined as exposure to at least one of the drugs mentioned among the six quality indicators.</description>
        <time_frame>Index admission (at randomization) and index discharge (duration of index admission, mean days 8.7)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention Group</title>
            <description>Medication review: In the intervention, the pharmacist will evaluate:&#xD;
Is there an indication for the drug?&#xD;
Has the drug desired effect?&#xD;
Is the dose correct and dosing scheme correct?&#xD;
Side effects, contraindications, inappropriate drugs&#xD;
Interactions&#xD;
Treatment time&#xD;
Cost effectiveness&#xD;
Adherence to recommendation list&#xD;
Problems with handling the drugs (for example crushing of the tablets)&#xD;
Untreated indication&#xD;
Double medications&#xD;
Administration of drugs</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Usual Care where no medication review is performed by clinical pharmacists</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Number of Participants With Potentially Inappropriate Medications, According to the Swedish National Board of Health and Welfare, at Admission and Discharge Between Intervention and Control Group</title>
          <description>Six drug-specific quality indicators as defined by the Swedish National Board of Health and Welfare were used to define use of Potentially inappropriate medications (PIMs) in this study. Four out of the six selected indicators belong to a group where drug-use should be as low as possible regardless of indication: anticholinergic drugs (as defined by the Swedish National Board of Health and Welfare, propiomazine, tramadol, and long-acting benzodiazepines. The two remaining indicators are classified as preparations for which correct and current indication is of particular importance: antipsychotic drugs (N05A except lithium) and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). In the present study, a PIM was defined as exposure to at least one of the drugs mentioned among the six quality indicators.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Time From Discharge to Drug-related Readmission</title>
        <description>Time from discharge to drug-related readmission among the whole sample, post-hoc</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Medication Review</title>
            <description>Medication review: In the intervention, the pharmacist will evaluate:&#xD;
Is there an indication for the drug?&#xD;
Has the drug desired effect?&#xD;
Is the dose correct and dosing scheme correct?&#xD;
Side effects, contraindications, inappropriate drugs&#xD;
Interactions&#xD;
Treatment time&#xD;
Cost effectiveness&#xD;
Adherence to recommendation list&#xD;
Problems with handling the drugs (for example crushing of the tablets)&#xD;
Untreated indication&#xD;
Double medications&#xD;
Administration of drugs</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
          </group>
        </group_list>
        <measure>
          <title>Time From Discharge to Drug-related Readmission</title>
          <description>Time from discharge to drug-related readmission among the whole sample, post-hoc</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
                <count group_id="O2" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1" spread="0.30"/>
                    <measurement group_id="O2" value="28.1" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intervention Group</title>
          <description>Medication review: In the intervention, the pharmacist will evaluate:&#xD;
Is there an indication for the drug?&#xD;
Has the drug desired effect?&#xD;
Is the dose correct and dosing scheme correct?&#xD;
Side effects, contraindications, inappropriate drugs&#xD;
Interactions&#xD;
Treatment time&#xD;
Cost effectiveness&#xD;
Adherence to recommendation list&#xD;
Problems with handling the drugs (for example crushing of the tablets)&#xD;
Untreated indication&#xD;
Double medications&#xD;
Administration of drugs</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Usual Care where no medication review is performed by clinical pharmacists</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="217"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Maria Gustafsson</name_or_title>
      <organization>Umeå University</organization>
      <phone>0046703978717</phone>
      <email>maria.gustafsson@umu.se</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

